Abbott Laboratories Stock Underperforms Tuesday When Compared To Competitors

Dow Jones

2025.12.02 21:34

I'm PortAI, I can summarize articles.

Abbott Laboratories' stock fell 1.32% to $126.32 on Tuesday, underperforming compared to competitors like Johnson & Johnson, Pfizer, and Merck. This marks the second consecutive day of losses for Abbott, closing 10.56% short of its 52-week high. Trading volume was below the 50-day average. The S&P 500 and Dow Jones both rose during the session.

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Abbott Laboratories (ABT) slipped 1.32% to $126.32 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.25% to 6,829.37 and the Dow Jones Industrial Average rising 0.39% to 47,474.46. This was the stock's second consecutive day of losses. Abbott Laboratories closed 10.56% short of its 52-week high of $141.23, which the company reached on March 4th. The stock underperformed when compared to some of its competitors Tuesday, as Johnson & Johnson (JNJ) rose 0.04% to $205.42, Pfizer Inc. (PFE) fell 0.47% to $25.15, and Merck & Co. Inc. (MRK) fell 0.79% to $101.03. Trading volume (5.4 M) remained 946,911 below its 50-day average volume of 6.3 M. Data source: Dow Jones Market Data, FactSet. Data compiled December 2, 2025. This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. (END) Dow Jones Newswires 12-02-25 1634ET